Zobrazeno 1 - 10
of 56
pro vyhledávání: '"Matthew Dankner"'
Autor:
David J.H. Bian, Anna-Maria Lazaratos, Sarah M. Maritan, Andrea Quaiattini, Zhimin Zeng, Zhengfei Zhu, Ugur Sener, Rachna Malani, Yu Jung Kim, Eiki Ichihara, Victor Cohen, April A.N. Rose, Nathaniel Bouganim, Matthew Dankner
Publikováno v:
Heliyon, Vol 10, Iss 9, Pp e29668- (2024)
Purpose: Leptomeningeal metastasis (LM) is a severe complication of non-small cell lung cancer (NSCLC). In patients with NSCLC LM harboring epidermal growth factor receptor (EGFR) mutations, osimertinib is favored over alternative EGFR tyrosine kinas
Externí odkaz:
https://doaj.org/article/47982575b8604d17a509444a6786dbf3
Autor:
Anna-Maria Lazaratos, Sarah M. Maritan, Andrea Quaiattini, Amelie Darlix, Ivica Ratosa, Emanuela Ferraro, Gaia Griguolo, Valentina Guarneri, Alessia Pellerino, Silvia Hofer, William Jacot, Hans-Joachim Stemmler, Marcel P.H. van den Broek, Nika Dobnikar, Francois Panet, Zubin Lahijanian, Aki Morikawa, Andrew D. Seidman, Riccardo Soffietti, Lawrence Panasci, Kevin Petrecca, April A.N. Rose, Nathaniel Bouganim, Matthew Dankner
Publikováno v:
Breast, Vol 69, Iss , Pp 451-468 (2023)
Background: Patients with HER2+ breast cancer (BC) frequently develop leptomeningeal metastases (LM). While HER2-targeted therapies have demonstrated efficacy in the neoadjuvant, adjuvant, and metastatic settings, including for parenchymal brain meta
Externí odkaz:
https://doaj.org/article/288dc5a91a0448019b1bab6e5490ad1c
Autor:
Giorgia Guaitoli, Lodovica Zullo, Marcello Tiseo, Matthew Dankner, April AN Rose, Francesco Facchinetti
Publikováno v:
Drugs in Context, Vol 12, Pp 1-19 (2023)
BRAF mutations are reported in about 3–5% of non-small-cell lung cancer (NSCLC), almost exclusively in adenocarcinoma histology, and are classified into three different classes. The segmentation of BRAF mutations into V600 (class 1) and non-V600 (c
Externí odkaz:
https://doaj.org/article/bf8987148ca8470591581cb620ec58f8
Autor:
Stephanie P. Totten, Young Kyuen Im, Eduardo Cepeda Cañedo, Ouafa Najyb, Alice Nguyen, Steven Hébert, Ryuhjin Ahn, Kyle Lewis, Benjamin Lebeau, Rachel La Selva, Valérie Sabourin, Constanza Martínez, Paul Savage, Hellen Kuasne, Daina Avizonis, Nancy Santos Martínez, Catherine Chabot, Adriana Aguilar-Mahecha, Marie-Line Goulet, Matthew Dankner, Michael Witcher, Kevin Petrecca, Mark Basik, Michael Pollak, Ivan Topisirovic, Rongtuan Lin, Peter M. Siegel, Claudia L. Kleinman, Morag Park, Julie St-Pierre, Josie Ursini-Siegel
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-20 (2021)
Complex I inhibition induces oxidative stress leading to cancer cell cytotoxicity. Here, the authors show, in breast cancer models, that inflammatory mediators can potentiate complex I inhibitor phenformin cytotoxicity through STAT1-mediated downregu
Externí odkaz:
https://doaj.org/article/e78e979f7f9a43d280222791ea6273df
Autor:
Shivshankari Rajkumar, Diana Berry, Kayla A. Heney, Colton Strong, LeeAnn Ramsay, Mathieu Lajoie, Rached Alkallas, Tan-Trieu Nguyen, Cameron Thomson, Mozhdeh Ahanfeshar-Adams, Matthew Dankner, Teresa Petrella, April A.N. Rose, Peter M. Siegel, Ian R. Watson
Publikováno v:
Cell Reports, Vol 39, Iss 1, Pp 110634- (2022)
Summary: Although combination BRAF/MEK inhibition has produced significant survival benefits for BRAF p.V600 mutant melanomas, targeted therapies approved for BRAF non-p.V600 mutant melanomas remain limited. Through the analysis of 772 cutaneous mela
Externí odkaz:
https://doaj.org/article/640812e1a89846ff8e8c5f518bbb3180
Publikováno v:
The Journal of Pathology: Clinical Research, Vol 6, Iss 3, Pp 163-170 (2020)
Abstract Given recent advances in the treatment of cancer, patients are surviving longer but frequently develop treatment‐resistant and inoperable metastases. Biomedical research has advanced to the stage where in‐depth study of these lesions is
Externí odkaz:
https://doaj.org/article/a8051a04b89c47419a442cb0acb206b7
Autor:
Kyle Lewis, Alex Kiepas, Jesse Hudson, Julien Senecal, Jacqueline R. Ha, Elena Voorand, Matthew G. Annis, Valerie Sabourin, Ryuhjin Ahn, Rachel La Selva, Sébastien Tabariès, Brian E. Hsu, Matthew J. Siegel, Matthew Dankner, Eduardo Cepeda Canedo, Mathieu Lajoie, Ian R. Watson, Claire M. Brown, Peter M. Siegel, Josie Ursini-Siegel
Publikováno v:
Breast Cancer Research, Vol 22, Iss 1, Pp 1-19 (2020)
Abstract Background The p66ShcA redox protein is the longest isoform of the Shc1 gene and is variably expressed in breast cancers. In response to a variety of stress stimuli, p66ShcA becomes phosphorylated on serine 36, which allows it to translocate
Externí odkaz:
https://doaj.org/article/3438a5e4c9ae4d46bf14a48ac898942d
Autor:
Matthew Dankner
Publikováno v:
McGill Journal of Medicine, Vol 15, Iss 1 (2020)
Externí odkaz:
https://doaj.org/article/6e81fa2163954415834b2e1a43d59a82
Publikováno v:
McGill Journal of Medicine, Vol 18, Iss 1 (2020)
The Canadian government recently announced, to much fanfare, that they have begun procuring the supplies that will be essential for mass vaccination against COVID-19, beginning with an agreement for 75 million syringes, alcohol swabs and bandages. Th
Externí odkaz:
https://doaj.org/article/73786a7f2f804824bbe9ca7117d5d4c3
Publikováno v:
OncoImmunology, Vol 6, Iss 7 (2017)
CEACAM1 is an extensively studied cell surface molecule with established functions in multiple cancer types, as well as in various compartments of the immune system. Due to its multi-faceted role as a recently appreciated immune checkpoint inhibitor
Externí odkaz:
https://doaj.org/article/98b3dee6868f400ca9db97305c597005